Many metabolic enzymes have been studied as targets for cancer treatment, such as GLUT1 inhibitor STF-31, HK2 inhibitor phenylnitrobenzylhydrazine, LDHA inhibitor NCI-006D, etc 20-22. The gene discussed is SLC2A1; the disease is cancer.